Scancell Holdings plc (AIM:SCLP)
London
· Delayed Price · Currency is GBP · Price in GBX 13.75
+0.75 (5.77%)
Apr 28, 2026, 5:15 PM GMT
Scancell Holdings Revenue
Scancell Holdings had revenue of 4.71M GBP in the twelve months ending October 31, 2025. In the fiscal year ending April 30, 2025, Scancell Holdings had annual revenue of 4.71M.
Revenue
4.71M
Revenue Growth
n/a
P/S Ratio
30.29
Revenue / Employee
78.52K
Employees
60
Market Cap
142.69M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bioventix | 12.54M |
| Faron Pharmaceuticals Oy | 1.14M |
| 4basebio | 1.78M |
| Ondine Biomedical | 1.18M |
| PureTech Health | 4.66M |
| hVIVO | 49.66M |
| Avacta Group | 113.00K |
| ImmuPharma | -69.96K |
Scancell Holdings News
- 3 months ago - Scancell Holdings Earnings Call Transcript: H1 2026 - Transcripts
- 3 months ago - Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma - GlobeNewsWire
- 4 months ago - Scancell Holdings Transcript: Study update - Transcripts
- 8 months ago - Scancell Holdings Earnings Call Transcript: H2 2025 - Transcripts
- 8 months ago - Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025 - GlobeNewsWire
- 10 months ago - Scancell Holdings Transcript: Study update - Transcripts
- 10 months ago - Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+ - GlobeNewsWire
- 10 months ago - Scancell Holdings Transcript: Status update - Transcripts